Tempest Therapeutics, Inc. (TPST) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Tempest Therapeutics reported revenue of $0. Net income was -$26.3M, or -$6.33 per diluted share. Operating activities generated -$26.8M of cash. At fiscal year end, Tempest Therapeutics held $16.9M in total assets against $10.3M in total liabilities, including $7.7M of cash and equivalents.
Open the full interactive Tempest Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Tempest Therapeutics Key Stats
| Share Price | $0.68 |
|---|---|
| Market Cap | $10.4M |
| 52-Week Range | $0.68 – $11.83 |
| Shares Outstanding | 15.2 million (basic, 2026 Q2) |
Tempest Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$36.0M | -$27.0M | -$34.6M | -$29.2M | -$42.0M | -$26.6M |
| Pre-Tax Income | -$36.4M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M |
| Income Tax | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$36.4M | -$28.3M | -$35.7M | -$29.5M | -$41.8M | -$26.3M |
| Diluted EPS | -$376.35 | -$97.11 | -$40.17 | -$24.83 | -$19.50 | -$6.33 |
Tempest Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.5M | -$4.0M | -$27.7M | -$5.2M |
| Diluted EPS | -$0.79 | -$0.97 | -$2.53 | -$0.34 |
Tempest Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.2M | $51.8M | $31.2M | $39.2M | $30.3M | $7.7M |
| Current Assets | $40.9M | $69.0M | $33.0M | $40.4M | $31.5M | $8.3M |
| Total Assets | $43.4M | $73.2M | $46.1M | $51.6M | $41.5M | $16.9M |
| Current Liabilities | $8.0M | $20.0M | $7.3M | $9.4M | $14.2M | $3.3M |
| Total Long-Term Debt | $300,000 | $15.1M | $10.4M | $10.5M | $6.4M | — |
| Total Liabilities | $9.7M | $37.1M | $28.0M | $24.8M | $22.4M | $10.3M |
| Shareholders' Equity | $33.1M | $36.1M | $18.1M | $26.8M | $19.1M | $6.7M |
Tempest Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$30.4M | -$26.0M | -$31.1M | -$27.4M | -$33.0M | -$26.8M |
| Cash From Investing | -$26,000 | -$97,000 | -$562,000 | -$170,000 | -$435,000 | $0 |
| Cash From Financing | $5.4M | $59.1M | $11.4M | $35.6M | $24.5M | $4.3M |
| Free Cash Flow | -$30.5M | -$26.1M | -$31.6M | -$27.5M | -$33.5M | -$26.8M |
Figures from Tempest Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tempest Therapeutics financials page for every line item.
Tempest Therapeutics Company Profile
| Ticker | TPST |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Brisbane, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001544227 |
Frequently Asked Questions
What was Tempest Therapeutics' revenue in fiscal 2025?
Tempest Therapeutics (TPST) reported revenue of $0 for fiscal 2025.
What is Tempest Therapeutics' annual revenue history?
Tempest Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Tempest Therapeutics' net income in fiscal 2025?
Tempest Therapeutics reported net income of -$26.3M for fiscal 2025.
What was Tempest Therapeutics' earnings per share (EPS) in fiscal 2025?
Tempest Therapeutics' diluted EPS was -$6.33 for fiscal 2025 (adjusted for any later stock splits).
What was Tempest Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tempest Therapeutics reported revenue of $0.
How many shares of Tempest Therapeutics are outstanding?
Tempest Therapeutics reported a weighted average of 15.2 million basic shares outstanding in 2026 Q2.
What is Tempest Therapeutics' market cap?
Based on its latest closing price, Tempest Therapeutics (TPST) has a market capitalization of about $10.4M.
When does Tempest Therapeutics' fiscal year end?
Tempest Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Tempest Therapeutics headquartered?
Tempest Therapeutics lists its business address in Brisbane, California in its SEC filings.